Co-Diagnostics Expands Cloud Infrastructure in India to Support TB Testing and Data Commercialization
Event summary
- Co-Diagnostics launched an integrated cloud and mobile infrastructure in India on September 3, 2026.
- The infrastructure supports ongoing clinical studies for its point-of-care Mycobacterium tuberculosis (MTB) test.
- The localized cloud environment complies with Indian data privacy and cybersecurity requirements.
- The platform allows mobile-based test analysis in decentralized settings with offline capabilities.
- Co-Diagnostics plans to replicate this architecture in Saudi Arabia and South Africa.
The big picture
Co-Diagnostics' move into India with a localized cloud and mobile infrastructure underscores the growing trend of digital health solutions in emerging markets. The company's strategy to aggregate and anonymize data for public health surveillance and potential commercialization aligns with broader industry shifts towards data-driven diagnostics and AI-enhanced disease monitoring. The success of this deployment could set a precedent for similar initiatives in other regions with significant public health needs.
What we're watching
- Regulatory Approval
- Whether the Co-Dx PCR platform will gain regulatory clearance in key markets, including India, Saudi Arabia, and South Africa.
- Data Monetization
- How Co-Diagnostics will commercialize anonymized data generated through its platform for public health and other uses.
- Market Expansion
- The pace at which Co-Diagnostics can replicate its cloud infrastructure in additional international markets.